Moderna and Merck disclosed positive Phase 3 topline results for intismeran autogene, their individualized neoantigen cancer vaccine, in INTerpath-001 (NCT05933577). In a 1,137-participant study, adding intismeran to Merck’s pembrolizumab reduced the risk that surgically removed melanoma would recur or spread. Company statements highlighted improvements across recurrence-free survival (primary endpoint) and distant metastasis-free survival (key secondary endpoint). The results reinforce the companies’ earlier mid-stage signals and sharpen investor focus on individualized mRNA approaches in solid tumors. Market reaction extended beyond the sponsors to sequencing and diagnostic supply chains that support neoantigen discovery and monitoring, underscoring how manufacturing and biomarker workflows are becoming central to the next wave of mRNA oncology.